Neovia Oncology, a Bellevue, Washington-based clinical-stage company, has entered a research collaboration with Monmouth Junction, New Jersey-based Creatv Bio, a division of Creatv MicroTech, Inc., to deploy liquid biopsy technology in upcoming studies of NEV-801, a dual-mechanism small molecule candidate targeting multiple drug resistance (MDR) in advanced solid tumors. The arrangement will integrate Creatv Bio's LifeTracDx blood test into Neovia's clinical program, generating translational and biomarker data intended to improve patient stratification and characterize treatment response. Financial terms were not disclosed.
NEV-801 is described by Neovia as a structurally linked dual-pharmacophore small molecule that simultaneously inhibits Topoisomerase I and Topoisomerase II activity, HIF-1 transcriptional activation, hypoxic induction of VEGF mRNA and protein expression, and Werner syndrome protein, a RecQ helicase implicated in DNA repair. The molecule combines analogs related to irinotecan and etoposide within a plasma-stable architecture designed for controlled release in the tumor microenvironment. This multi-target design is intended to reduce resistance escape — a common limitation of single-mechanism cytotoxics — by engaging several cancer cell survival pathways simultaneously with a single compound. Neovia also references NEV-801 as a potential foundation for future antibody-drug conjugate payload development, though no formal ADC program has been disclosed.
Creatv Bio's contribution centers on its LifeTracDx blood test, which uses CellSieve microfilters to isolate Cancer Associated Macrophage-Like Cells and Circulating Tumor Cells from peripheral blood. The platform is analytically validated for research and development use and operates from a CLIA-certified laboratory. In this collaboration, the technology is intended to monitor drug targets and generate information on patient treatment response as NEV-801 advances into late-line therapy studies in patients with advanced, heavily pretreated multiple drug resistant solid tumors.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Spot something wrong? Report an issue with this article